Series of large decreases among pricey hepatitis C therapies

Prices of new hepatitis C therapies, which reached tens of thousands of wons with availability of full recovery, were largely reduced when entering the domestic market.

According to the recent ‘Insured Drug List and Ceiling Price Table’ officially informed by the Ministry of Health and Welfare(MOHW), the ceiling price of a Gilead’s hepatitis C treatment ‘Harvoni(generic name: ledipasvir+sofosb...